Global Retinoblastoma Market - 2023-2030

Global Retinoblastoma Market - 2023-2030

Global retinoblastoma market reached US$ XX billion in 2022 and is expected to reach US$ XX billion by 2030 growing with a CAGR of XX% during the forecast period 2023-2030.

The global retinoblastoma market experiencing significant growth in recent years. This type of eye cancer is most common in children younger than age 5, but in rare cases, it can develop in older children or adults. Retinoblastoma treatment depends on whether it is intraocular (within the eye) or extraocular (outside the eye), and on the size of the tumor. Treatment options include chemotherapy, cryotherapy (freeze treatment), laser therapy, radiation, and surgery among others. Cancer can spread in the three ways such as tissue, the lymph system, and the blood.

The increasing prevalence of retinoblastoma in children, growing awareness and early diagnosis, increasing demand for innovative drugs and treatments for the better treatment, increasing clinical trials and research activities, and technological advancements in diagnostic methods are the major factors expected to drive the global retinoblastoma market.

Dynamics

Increasing Demand for Innovative Drugs and Treatments Drives the Growth of the Retinoblastoma Market

In recent years, the demand for innovative drugs and treatments are increasing for enhanced patient outcomes due to the increasing prevalence of retinoblastoma in children. Personalized medicine involves tailoring treatments to individual patients based on their unique genetic profile and disease characteristics gained prominence in oncology including retinoblastoma. The demand for innovative drugs in retinoblastoma is continuously increasing to provide more precise and effective therapies, potentially leading to better treatment outcomes.

For instance, on February 14, 2023, Alephoson Biopharmaceuticals Ltd. disclosed peptide-drug conjugates comprising a cell-penetrating peptide covalently linked to melphalan that is reported to be useful for the treatment of retinoblastoma.

Moreover, many clinical trials and research activities are going on rapidly, leading to many innovative inventions for better treatment. The innovative treatment options also include technological advancements, these advancements help in a better understanding of the disease and its mechanisms resulting in better and enhanced patient outcomes. Hence, many clinical trials and research activities are even going on for innovative treatment options.

Similarly, on June 09, 2022, Synthetic Biologics, Inc. announced that VCN-01, a genetically modified oncolytic adenovirus received orphan drug designation by the FDA for the treatment of patients with retinoblastoma (RB).

Growing Awareness and Early Diagnosis Also Drive the Growth of the Retinoblastoma Market

Increasing awareness about retinoblastoma results in the potential benefits of early diagnosis and better treatment. Awareness of retinoblastoma plays a crucial role in enhanced treatment and it can be completely curable if detected early. With improved techniques and technologies, the survival of children with retinoblastoma has improved but low awareness is still a cause of concern, so increasing awareness leads to early detection in many children.

For instance, on 14 February 2023, a new campaign launched by the Pan American Health Organization (PAHO), St. Jude Children’s Research Hospital, and Childhood Cancer International aims to alert parents, caregivers, and health professionals about the retinoblastoma in Latin America and the Caribbean about the first signs of the most common cancers in children and adolescents to improve timely diagnosis and treatment outcome.

Moreover, the tumor is not very common in the world, the incidence in India is about 1 in 10,000 live births each year, affecting either one or both eyes. In Latin America and the Caribbean, nearly 29,000 children and adolescents are diagnosed with this type of cancer each year. This rare childhood eye cancer affects around 50 babies and children in the UK every year. Hence, increasing awareness leads to early diagnosis and early treatment.

For instance, on May 15, 2023, Sankara Nethralaya, an eye hospital holds an awareness week on retinoblastoma. Called the white monster, cancer of the eye affects children under the age of three, it is the alteration of the red reflex or asymmetrical red reflex or white reflex in the center of an eye or both eyes.

High Treatment Costs Will Hamper the Growth of the Market

The targeted therapies are showing promising results in clinical trials, but they can be costly to develop and manufacture. The research and development costs for these innovative treatments, coupled with the expenses of conducting clinical trials, may lead to higher prices for these drugs, impacting their affordability for patients seeking retinoblastoma treatment.

The management of retinoblastoma type of cancer may involve prolonged treatment, including chemotherapy, radiation therapy, and surgeries. These long-term treatments can result in very high costs that can become a burden for patients and their families. Even the high treatment costs also become a burden for many healthcare providers, this resulting in hampering the growth of the retinoblastoma market.

Segment Analysis

The global retinoblastoma market is segmented based on disease type, treatment type, end-user and region.

The Non-Hereditary Retinoblastoma from Disease Type Segment Accounted for Approximately 35.7% of the Retinoblastoma Market Share

The non-hereditary retinoblastoma is also known as sporadic retinoblastoma. About 60% of children with retinoblastoma have non-hereditary retinoblastoma. Commonly, children are born with 2 normal copies of the RB1 gene. A mutation of both copies of the RB1 gene in a retinoblast causes a retinoblastoma tumor to form in the eye of the children. Children with non-hereditary retinoblastoma only develop a tumor in one eye known as unilateral retinoblastoma. They will not usually pass the RB1 mutation on to their future children.

Like all types of retinoblastoma, there is an easiest way to detect the abnormality in the eye of retinoblastoma children which is by a whitish spot in the pupil when the eye is exposed to direct light. It is often visible in pictures, because of the flash. If the spot called leukocoria is detected, then, the parents should be aware of the early diagnosis and better treatment. Since biopsies pose a threat to vision, scan tests such as MRIs and ultrasounds are typically used to look for tumors behind the eyes.

Geographical Penetration

North America Accounted for Approximately 41.2% of the Market Share, Owing to the Increasing Prevalence and Strong Presence of Major Players

Though the retinoblastoma is a rare disease, there is a high prevalence of this type of cancer in North America. The availability of comprehensive cancer treatments and advanced diagnostic capabilities allows for better disease monitoring, management, and treatment. According to the National Cancer Institute, there are 200 to 350 children in the United States who are estimated to be diagnosed annually with the disease.

North America, especially the United States is home to several major pharmaceutical companies, medical device manufacturers, and research institutions that are actively involved in the development and commercialization of retinoblastoma drugs and treatments. The region's established pharmaceutical and healthcare sectors attract significant investments and foster innovations in the retinoblastoma treatments.

Competitive Landscape
The major global players in the retinoblastoma market include Pfizer Inc., Bristol Myers Squibb Company, Teva Pharmaceutical Pvt Ltd., Merck and Co., Novartis AG, GlaxoSmithKline PLC., Johnson & Johnson, Baxter International, Inc., AbbVie Inc., and Hikma Pharmaceuticals PLC among others.

COVID-19 Impact Analysis

The COVID-19 pandemic significantly impacted the global retinoblastoma market. During the pandemic, mainly the healthcare systems faced the pressure to manage COVID-19 cases, leading to delayed regular healthcare services. Non-urgent medical appointments and elective surgeries are postponed or canceled to prioritize COVID-19 patients and reduce the risk of transmission. As a result, some children with retinoblastoma experienced delayed diagnosis and treatment, potentially affecting their treatment outcomes.

Russia-Ukraine Conflict Analysis

The Russia-Ukraine conflict is estimated to have a moderate impact on the global retinoblastoma market. The conflict disrupts the retinoblastoma research-related activities and clinical trials. Many clinical trials and research activities related to retinoblastoma type of cancer were temporarily disrupted in the conflict regions, even led to the lack of many innovative treatment options globally.

Segmentation

By Disease Type
• Non-hereditary retinoblastoma (sporadic retinoblastoma)
• Hereditary retinoblastoma (familial retinoblastoma)

By Treatment Type
• Surgery
• Radiation Therapy
• Cryotherapy
• Laser Therapy
• Chemotherapy
• Others

By End-User
• Hospitals
• Ophthalmic Clinics
• Cancer Research Centers
• Ambulatory Surgical Centers
• Others

By Region
• North America
U.S.
Canada
Mexico
• Europe
Germany
U.K.
France
Spain
Italy
Rest of Europe
• South America
Brazil
Argentina
Rest of South America
• Asia-Pacific
China
India
Japan
Australia
Rest of Asia-Pacific
• Middle East and Africa

Key Developments
• On May 14, 2023, The Childhood Eye Cancer Trust (CHECT) released resources for healthcare professionals to help raise awareness of retinoblastoma. Ahead of World Retinoblastoma Awareness Week, held from 14–20 May, CHECT has created assets that professionals can use on social media to outline the signs and symptoms of retinoblastoma.
• On Feb. 8, 2022, Synthetic Biologics, Inc., a diversified clinical-stage company developing therapeutics designed to treat diseases in areas of high unmet need, announced that VCN Biosciences, S.L.'s VCN-01 received Orphan Drug Designation for retinoblastoma from the U.S. Food & Drug Administration (FDA). This announcement follows Synthetic Biologics' recent announcement that it had entered a definitive agreement to acquire VCN, which is subject to conditions that must be met prior to closing. VCN is developing a new oncolytic adenovirus (OV) platform designed to trigger tumor cell death and promote immune cell infiltration into tumors.

Why Purchase the Report?
• To visualize the global retinoblastoma market segmentation based on disease type, treatment type, end-user and region as well as understand key commercial assets and players.
• Identify commercial opportunities by analyzing trends and co-development.
• Excel data sheet with numerous data points of retinoblastoma market-level with all segments.
• PDF report consists of a comprehensive analysis after exhaustive qualitative interviews and an in-depth study.
• Product mapping available as excel consisting of key products of all the major players.

The global retinoblastoma market report would provide approximately 53 tables, 54 figures, and 195 Pages.

Target Audience 2023
• Manufacturers/ Buyers
• Industry Investors/Investment Bankers
• Research Professionals
• Emerging Companies